2 20 years later, 'The Far Side' is still far out, and the new collection is lighter! By feeds.scpr.org Published On :: Tue, 02 Dec 2014 06:00:31 -0800 One of 4,000 "The Far Side" panels Gary Larson drew over 14 years. The full collection is now out in paperback.; Credit: Gary Larson Charles SolomonOff-Ramp animation expert Charles Solomon reviews "The Complete Far Side: 1980-1994" by Gary Larson. It’s hard to believe the last panel of Gary Larson’s wildly popular comic strip “The Far Side” ran 20 years ago: January 1, 1995. The comics page of the LA Times (and many other papers) still feels empty without it. RELATED: Charles Solomon interviews artists responsible for look of "Big Hero 6" During its 14-year run, "The Far Side" brought a new style of humor to newspaper comics that was weird, outré and hilarious. The strip became an international phenomenon, appearing in over 1,900 newspapers worldwide. Larson won both the National Cartoonists' Society Reuben Award for Outstanding Cartoonist of the Year and the Best Syndicated Panel Award. An exhibit of original artwork from the strip broke attendance records at natural history museums in San Francisco, Denver and here in L.A. Fans bought tens of millions of "Far Side" books and calendars. Much of the humor in “The Far Side” derived from Larson's seemingly effortless juxtaposition of the mundane and bizarre. When a bug-housewife declares "I'm leaving you, Charles...and I'm taking the grubs with me," it's the utter normalcy of the scene that makes it so funny. Mrs. Bug wears cats eye glasses, while Mr. Bug reads his newspaper in an easy chair with a doily on the back. Or, a mummy sits an office waiting room reading a magazine while a secretary says into the intercom, “Mr. Bailey? There’s a gentlemen here who claims an ancestor of your once defiled his crypt, and now you’re the last remaining Bailey and … oh, something about a curse. Should I send him in?” "The Complete Far Side" contains every strip ever syndicated: more than 4,000 panels. It should probably come with a warning label, "Caution: reading this book may result in hyperventilation from uncontrollable laughter." Except for a few references to Leona Helmsley or other now-forgotten figures, Larson’s humor remains as offbeat and funny as it was when the strips were first printed. Andrews and McMeel initially released this collection in 2003 in two hardbound volumes that weighed close to 10 pounds apiece. You needed a sturdy table to read them. The three volumes in the paperback re-issue weigh in around three pounds and can be held comfortably in the lap for a while. Because “The Far Side” ended two decades ago, many people under 30 don’t know it. The reprinted collection offers geezers (35 or older) a chance to give a present that should delight to that impossible-to-shop-for son, daughter, niece or nephew. How often does an older adult get a chance to appear cool at Christmas or Hanuka? And if that ingrate kid doesn’t appreciate it, "The Complete Far Side" also makes an excellent self-indulgence. Charles Solomon lends his animatio expertise to Off-Ramp and Filmweek on Airtalk, and has just been awarded the Annie's (The International Animated Film Society) June Foray Award, "for his significant and benevolent or charitable impact on the art and industry of animation." Congratulations, Charles! This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 12 anime gift suggestions for the clueless parent By feeds.scpr.org Published On :: Fri, 19 Dec 2014 05:30:21 -0800 "Sailor Moon" cosplayers at Anime Revloution 2014 in Vancouver, Canada.; Credit: GoToVan/Flickr Creative Commons Charles SolomonJapanese animation — anime — offers very different visions from its American counterparts, and it's extremely popular with college and high school students. They can be extremely difficult for well-meaning parents, uncles and aunts to shop for, so here, in no particular order, are some titles that can transform an adult’s image from clueless doofus to knowing friend. Plus, we have a few suggestions for younger children (who can also be a pain to shop for). Cardcaptor Sakura: Complete Collection NIS America: $249.99; 9 discs, Blu-ray, plus book When cheerful fourth-grader Sakura Kinamoto opens an odd book in her father's study, strange lights fly out. Kerberos, who looks like a plushie of the lion on the book's cover, explains that she's inadvertently released a deck of magical cards. Despite her protests that’s she just an ordinary little girl, Kero insists Sakura must become a Cardcaptor and retrieve them before they work mischief on the world. Many American series talk about empowering girls — in this one, the viewer sees Sakura grow stronger and more confident as she learns to master the magical cards. Cowboy Bebop: The Complete Series Funimation: $59.98; Blu-ray, 4 discs The sci-fi action series "Cowboy Bebop" redefined cool in animation when it debuted in 1998. Twenty-first-century bounty hunter Spike Spiegel is an anti-hero in the tradition of '40s film noir detectives. Spike is a tough guy; a crack shot, an ace pilot and a skilled martial artist. But his cynical exterior conceals a never-healed wound left by the woman he loved and lost. Seventeen years later, "Cowboy Bebop" is so popular that two special editions of the series for holiday gifting have already sold out (!). But it’s available on DVD and Blu-ray. Dragon Ball Z: Battle of the Gods Funimation: $34.98; DVD/Blu-ray combo pack; 3 discs The first new "Dragon Ball Z" animation in 17 years, "Battle of the Gods" (2013) proved how popular the franchise still is, selling over 1 million tickets in just six days in Japan. The filmmakers keep the animation flat, limited and hand-drawn, so "Battle of the Gods" looks like the classic TV series and delivers the mixture of slapstick, friendship and over-the-top battles Dragon Ball fans remember and want to see again — especially guys in their 20s who grew up watching it. Naruto Shippuden: Road to Ninja: The Movie 6 VIZ: $29.99 DVD/Blu-ray combo; 2 discs The title hero of the long-running "Naruto" and "Naruto Shippuden" series is a come-from-behind hero whose world centers on magical ninja techniques, outrageous fights, slapstick, friendship and ramen. "The Road to Ninja" incorporates these well-loved elements, but stresses the lonely, compelling side of the title character. Audiences would quickly weary of Naruto if he were just a knuckleheaded prankster. His dedication to overcoming his weaknesses and achieving his goals makes him heroic, as well as comic — and one of the most popular animated characters of the new millennium. (A scene from "Ranma 1/2," an anime series about a 16-year-old boy who's transformed into a girl whenever he's splashed with water.) Ranma 1/2: Sets 1, 2, 3 & 4 VIZ: $54.97 each, Blu-ray; $44.82, DVD: 3 discs Because he once fell into a cursed spring, black-haired high school martial artist Ranma Saotome turns into a buxom, red-haired girl when he’s hit with cold water. (Hot water restores his proper gender.) Ranma and his father Genma are freeloaders in the home of Suon Tendo. To ensure the continuation of the family dojo, the fathers have decided that the loutish Ranma and Suon’s hot-tempered daughter Akane are engaged. "Ranma 1/2" supplies the slapstick insanity animation can provide in abundance. The filmmakers carefully sneak in just enough grudging affection between Ranma and Akane to keep the series from feeling mean-spirited. Pokémon: Indigo League (Season 1): Complete Collection VIZ: $54.98 9 discs "Pokémon" is no longer the trend du jour it was 20 years ago, when it swept America. But the games and the animated series remain popular. Although it's product-based and sometimes cloying, "Pokémon" is an agreeable show for elementary school children that stresses friendship, perseverance, fair play and good sportsmanship. These early adventures take the main characters through the first part of the game in its original Red/Blue versions. With his friends Misty and Brock, aspiring master Pokémon trainer Ash Ketchum defeats other trainers, captures wild Pokémon and outwits the inept comic villains of Team Rocket. Princess Nine Complete Series Bayview Entertainment: $39.99 DVD Ryo Hayakawa inherited her late father’s talent as a pitcher, but she works as a waitress in her mother’s tiny cafe. Determined to overcome sexist opposition and create a girls’ baseball team that can compete in the national championships, Ms. Himuro, the head of prestigious Kisaragi High, gives Ryo a scholarship. She must recruit players and build an effective team. Ryo is a very likable character — she’s proud of her abilities, but surprised at where they take her. "Princess Nine" ranks among the better girls’ series of recent years, with characters who are strong, capable individuals but who exhibit human weaknesses. Short Peace Sentai Filmworks: $29.98 Blu-ray For "Short Peace," Katsuhiro Otomo ("Akira") and three other directors made short films in personal styles they felt suited the stories they’d chosen, two of them evoking the look of 19th century woodblock prints. In Shuhei Morita’s Oscar-nominated "Possessions," a wandering tinkerer seeks refuge from a storm in a remote forest shrine. Inside, he must pacify umbrellas, bowls and other household objects that resent being thrown away after years of devoted service. Otomo’s "Combustible" focuses on childhood sweethearts Owaka and Matsukichi, the son and daughter of wealthy merchants in 18th century Edo (Tokyo). The climactic blaze that brings the star-crossed lovers together — only to separate them forever — is stunningly beautiful. (Oscar-winning Japanese animator and film director Hayao Miyazaki walks past an advertisement following the release of his film "Ponyo.") No figure in contemporary animation is more admired than Hayao Miyazaki. Walt Disney Home Entertainment has just released to DVD/Blu-ray 2-disc sets of three of his major films at $26.95 each: Kiki's Delivery Service A charming coming-of-age story, "Kiki's Delivery Service" (1989) follows the very human ups and downs of an adolescent witch who must leave her family for a new city where she’ll discover her special talent. Kiki copes believably with tight budgets, self-doubt and the awkward attentions of a flight-obsessed boy. The late comedian Phil Hartman gave his final performance as Gigi, the sardonic black cat who provides a running commentary on Kiki's misadventures. Princess Mononoke The ecologically-themed "Princess Mononoke" (1999) was the first of Miyazaki’s features to receive a major theatrical release in the U.S. The problems posed by rampant development and consumerism figure prominently in the film. “If you want to discuss any aspect of the problems we face as humans, you cannot ignore ecology,'' he said. Miyazaki juxtaposes visually and emotionally intense scenes of the characters, with quiet images of clouds, streams and forests. When rain begins to fall, he lingers on a stone that darkens as it absorbs moisture. (A screenshot from Japanese director and animator Hayao Miyazaki's "Princess Mononoke.") The Wind Rises In "The Wind Rises" (2013), Miyazaki carries the viewer through rapturously beautiful fantasies, hard-won pleasures and poignant sorrows in this biopic of Jiro Horikoshi, who designed the A6M Zero Fighter for Mitsubishi during World War II. "The Wind Rises" isn’t focused on speed — Miyazaki concentrates on the magic of flight. Instead of launching the viewers on a CG rollercoaster ride, he enables them to savor the magic of escaping gravity in a way that approaches visual poetry. "The Wind Rises" may be Miyazaki’s last feature, but the director is still clearly at the height of his powers; although premature, it’s a glorious exit. Death Note: The Complete Series Light Yagami, the hero of the dark fantasy-adventure "Death Note" (2006) is brilliant, alienated— and murderous. He found the Death Note: the notebook of a Shinigami (god of death). If anyone writes the name of a human in the book, that person dies within minutes. Light launches a vigilante campaign to rid the world of criminals and create his vision of a perfect society. But the unexplained string of deaths attracts the attention of the police, who turn the case over to the secretive master crime solver known only as L. Although it begins slowly, "Death Note" gets better with each installment, as the stakes grow higher in the macabre duel of wits between Light and L. This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 Triple Play: What An Abbreviated 2020 MLB Season Might Look Like By feeds.scpr.org Published On :: Thu, 07 May 2020 09:04:32 -0700 People sit on a hill overlooking Dodger Stadium on what was supposed to be Major League Baseball's opening day, now postponed due to the coronavirus, on March 26, 2020 in Los Angeles, California. ; Credit: Mario Tama/Getty Images AirTalk®Had the 2020 MLB season started at the end of March like it was scheduled to, at this point we’d be starting to see divisions shape up, star pitchers and position players separating themselves from the rest of the league and a first look at who this year’s contenders and pretenders really would be. Sadly, the COVID-19 outbreak forced the league to postpone the start of the season, and now the question has become if there will be a season, not when. Not to be dragged down by the idea of no baseball, Wall Street Journal sports writer Jared Diamond took a recent proposal the league floated for an abbreviated 2020 campaign and gamed out how that might look in real life. The league’s idea would do away with the National and American Leagues and divide all 30 MLB teams into three divisions of 10 teams separated by region, and those teams would play in empty stadiums and only against other teams in their geographic division in the interests of reducing travel. But how viable is this, really? And what other considerations would the league and players union have to take with regards to testing and protocol for what happens if someone were to contract COVID-19? Is there a world where baseball still happens this year? Today on AirTalk, Jared Diamond joins the Triple Play of Larry Mantle, Nick Roman and A Martinez to talk about what a shortened 2020 MLB season might look like, which teams stand to win and lose the most from the realignment and what other precautions the league would have to take against the spread of COVID-19. Guests: Jared Diamond, national baseball writer for the Wall Street Journal; his new book is "Swing Kings: The Inside Story of Baseball's Home Run Revolution” (William Morrow, March 2020); he tweets @jareddiamond Nick Roman, host of KPCC’s “All Things Considered”; he tweets @RomanOnTheRadio A. Martinez, host of KPCC’s “Take Two”; he tweets @amartinezLA This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 The Perseids are back for their 2019 show By feeds.scpr.org Published On :: Wed, 14 Aug 2019 18:20:08 -0700 LAKE MEAD NRA, NV - AUGUST 12: Perseid meteors streak across the sky early August 12, 2008 near Rogers Spring in the Lake Mead National Recreation Area, Nevada. The meteor display, known as the Perseid shower because it appears to radiate from the constellation Perseus in the northeastern sky, is a result of Earth's orbit passing through debris from the comet Swift-Tuttle. Tuesday morning was considered the peak of the shower, which is visible every August. (Photo by Ethan Miller/Getty Images); Credit: Ethan Miller/Getty Images Jacob MargolisIt's August, which means the spectacular Perseids meteor shower is upon us. That said, they're not going to be nearly as bright as they could be given the moon.This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 How Will Chief Justice And Supreme Court Conservative Majority Affect 2020 Election? By feeds.scpr.org Published On :: Thu, 23 Apr 2020 04:40:18 -0700 ; Credit: J. Scott Applewhite/AP Nina Totenberg | NPRThe U.S. Supreme Court is no stranger to controversy, but it still gets higher marks in public opinion polls than the other branches of government. Now though, for the first time in memory, the court is not just split along ideological lines, but along political lines as well: All the conservatives are Republican appointees, all the liberals Democratic appointees. That division could put the court in the crosshairs of public opinion if it is forced to make decisions that affect the 2020 election. Chief Justice John Roberts has worked hard to persuade the public that the justices are fair-minded legal umpires--not politicians in robes. That image got pretty scuffed up earlier this month when the conservative court majority shot down accommodations for the coronavirus that would have allowed six more days for absentee ballots to be received in Wisconsin's election for 500 school board seats, over 100 judicial seats, and thousands of other state and local positions. In the weeks leading up to the election, the COVID-19 pandemic had become a public health crisis. Encouraged by local officials, about a million more voters than usual requested absentee ballots, and local officials were unable to keep up with the surge. To mitigate that problem, the lower courts allowed an extra six days for election officials to receive completed absentee ballots. But the day before the election, the Supreme Court overturned the lower court ruling by a 5-to-4 vote. The result was that tens of thousands of people who had not yet even received their absentee ballots were forced to, as the dissenters put it, choose between their health and their right to vote. The TV footage of people wearing masks waiting for hours to vote at the very few precincts that were open amid the pandemic was, to say the least, not a good look. Health officials in Milwaukee have since identified six voters and one poll worker who appear to have contracted the virus during the election. The majority opinion was unsigned, so no one knows who the principal author was. But we do know some things. First, the emergency appeal in the case came through the justice assigned to that region of the country, Brett Kavanaugh. Typically, when a justice refers a case to the full court, he or she writes a memo about the issues, likely with a recommendation. Kavanaugh almost certainly did that. But other justices would then chime in. And in a voting case, Chief Justice Roberts assuredly would have played a pivotal role. "John Roberts' fingerprints are on this as chief justice and as someone who has owned this area of the law," says Joan Biskupic, a Supreme Court biographer and CNN legal analyst who is the author of a critically acclaimed biography about Roberts. Indeed, Roberts was invested in voting-rights law as far back as 1982 when he was a staffer in the Reagan administration. Back then, he led the effort to narrow the landmark 1965 Voting Rights Act. When that failed, President Reagan signed the broad extension of the law, rejecting advice to veto it. But years later, on the Supreme Court, Roberts wrote the decision in Shelby County v. Holder, gutting a key provision of that law. So, it was no surprise when the conservative majority refused to make even a modest accommodation to the pandemic. What was surprising was the tone of the opinion. Critics of the opinion, including some Roberts defenders, called the language "callous," "cynical," and "unfortunate." In fact, the word "pandemic" appears not once in the court's unsigned opinion. Rather, the majority sought to portray the issue before the court as a "narrow, technical question." The majority said the lower court had overstepped the Supreme Court's established rule that courts should "ordinarily not alter the election rules on the eve of an election." The dissenters replied that the court's treatment of the current situation as ordinary "boggles the mind." Writing for the dissenters, Justice Ruth Bader Ginsburg opined that "a voter cannot deliver...a ballot she has not yet received. Yet tens of thousands of voters who timely requested absentee ballots" are being asked to do just that. "I do think there's something to this idea that we need to stick with the rules even in the context of an emergency," says law professor Rick Hasen, an election expert at the University of California, Irvine. He and others see the legal question before the court as a close call, but say the decision was, at the very least, tone deaf in light of the reality of a pandemic. Hasen says that the court could have recognized "the inhumanity of making people vote in this way," but that instead the tone of the opinion was "really dismissive of the entire threat facing these voters." Chief Justice Roberts has, on some occasions tried to bridge the two wings of the court, in a couple of big cases siding with the court's liberals, or sometimes trying to fashion a compromise. But as Hasen observes, "there really is not any case I can think of involving elections where Roberts has forged a larger consensus." Roberts must have anticipated at least some of the outcry over the Wisconsin decision. He is, after all, an astute political observer. But as any student of the court knows, Roberts is a reliable, and often leading member of the conservative majority when it comes to a whole host of issues involving campaigns, voting and elections. That includes decisions he has written striking down laws aimed at limiting the role of big money in campaigns and decisions upholding partisan gerrymanders. Moreover voting rights in particular "is an area of the law where John Roberts has not been deterred by anticipated public criticism," says Biskupic, his biographer. For the chief, says Biskupic, "It's not just voting rights. It's a broader overlay of representation" in his decisions, a pattern that "often will favor Republicans, but more fundamentally, it seems to favor entrenched powers, the status quo in many states, against ordinary citizens. And we certainly saw that in Wisconsin." Uncertainties around COVID-19 remain, with states facing decisions about when to reopen and what size of public gatherings are safe. As November inches closer, those decisions could affect the 2020 election. Who gets to vote, when, and how, are unanswered questions and states are surely exploring different plans to keep voters safe. But Roberts' Supreme Court may be the ultimate arbiter of what changes and accommodations to voting are allowed. The majority opinion "tried to tell the public that this was a very small decision," says Biskupic. "But as the dissent pointed out, it laid down a very serious marker about how voters will be accommodated in the middle of the coronavirus crisis." Copyright 2020 NPR. To see more, visit https://www.npr.org. This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 30% off GridinSoft Trojan Killer - Ends July 3rd, 2014 By www.bleepingcomputer.com Published On :: 2014-06-26T15:50:53-05:00 Full Article
2 10% - 20% off CryptoPrevent from Foolish IT By www.bleepingcomputer.com Published On :: 2014-07-25T15:53:04-05:00 Full Article
2 50% discount off a 2 years license of Trojan Killer - Ends August 10, 2014 By www.bleepingcomputer.com Published On :: 2014-07-31T15:06:57-05:00 Full Article
2 Exclusive: 6 months of BitDefender Internet Security 2015 for Free By www.bleepingcomputer.com Published On :: 2014-10-07T17:13:31-05:00 Full Article
2 New Deal: Aduro Surge Protector: 6-Outlet & 2-USB Port at 52% off. Ends Oct. 3rd By www.bleepingcomputer.com Published On :: 2015-09-28T09:41:55-05:00 Full Article
2 MATLAB R2020a By feedproxy.google.com Published On :: Mon, 04 May 2020 12:54:35 +0000 Sean's pick this week is MATLAB R2020a by MathWorks' Development. Contents New... read more >> Full Article Picks
2 2020 TCM Classic Film Festival Goes Virtual With Special Home Edition During COVID-19 By feeds.scpr.org Published On :: Fri, 17 Apr 2020 09:00:39 -0700 Closing Night Party at last year's 2019 TCM 10th Annual Classic Film Festival in Hollywood, California. ; Credit: Presley Ann/Getty Images for TCM FilmWeek®Like all public events following the start of widespread stay-at-home orders from the state and federal government, the 2020 TCM Classic Film Festival was unfortunately cancelled this year due to health concerns posed by COVID-19. But festival faithful and classic film buffs won’t be left hanging this year. Instead of a live, in person event, TCM decided to do a Special Home Edition of the annual festival that will air on the TCM Channel. The festival kicked off Thursday evening with a screening of the 1954 version of “A Star is Born” starring Judy Garland and James Mason and will include a number of films from past years’ festival lineups as well as ones that were slated for this year’s event. It ends late Sunday night (technically early Monday morning) with a screening of the 1982 film Victor/Victoria, for which Julie Andrews was slated to be in attendance at the 2020 festival before it was cancelled. Today on FilmWeek, Turner Classic Movies hosts Ben Mankiewicz and Dave Karger join Larry Mantle to preview this year’s Special Home Edition of the TCM Classic Film Festival, talk about having to pivot due to the pandemic, and sharing some of their favorite films that are screening at this year’s event. For a list of films and showtimes, click here. Guests: Ben Mankiewicz, host for Turner Classic Movies; he tweets @BenMank77 Dave Karger, host for Turner Classic Movies and special correspondent for the Internet Movie Database (IMDb); he tweets @DaveKarger This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 4 awesome discoveries you probably didn't hear about this week -- Episode 32 By feedproxy.google.com Published On :: 2019-08-31T07:00:00Z 4 awesome discoveries you probably didn't hear about this week -- Episode 32 Full Article
2 Tronox Shares Trade Up 25% on Preliminary Q1 Financial Results By feedproxy.google.com Published On :: Fri, 17 Apr 2020 00:00:00 PST Shares of Tronox Holdings traded higher after the company released preliminary Q1/20 earnings data and provided an update on its ongoing operations. Full Article
2 Ports see worst congestion since 2004 because of work stoppage By feeds.scpr.org Published On :: Mon, 09 Feb 2015 16:31:33 -0800 In this Jan. 14, 2015, photo, shipping containers are stacked up waiting for truck transport at the Port of Los Angeles.; Credit: Damian Dovarganes/AP Ben BergmanThe Ports of Los Angeles and Long Beach reopened Monday after ship loading and unloading was suspended this weekend because of a long-running labor dispute, which caused the worst delays the ports have seen in more than a decade. The stoppage led to a queue of 31 ships, according to Kip Louttit, Executive Director of the Marine Exchange of Southern California, the agency that manages ship traffic. “It’s quite unusual,” said Louttit. There was a 10-day lockout at the ports in 2002, and an eight-day strike by port clerks in 2012, but even during those standoffs, the queue never exceeded 30 vessels. The last time that happened was in 2004, because of staffing shortages at the Union Pacific Railroad. Some 65 ships were anchored, "backed up halfway down to San Diego, like 50 miles down the coast," Art Wong, spokesperson for the Port of Long Beach, told JOC.com, a container shipping and international supply chain industry website. By Monday afternoon, the situation had improved some: 24 vessels were waiting to dock. Louttit says all those ships waiting at sea means cargo is not getting where it needs to be. “We had an automaker from the Midwest stop by, trying to get an idea of what the flow would be, because their plants are running out of parts to make cars,” he said. Los Angeles Councilman Joe Buscaino, who supports the dockworkers union, called on both sides to reach an agreement quickly. To underscore the delays the dispute is having, he travelled a mile and a half out to sea Monday morning to count the number of anchored ships for himself. He posted a video of his trip on Youtube: This content is from Southern California Public Radio. View the original story at SCPR.org. Full Article
2 Win10 Cloned M2 SSD won't boot By www.bleepingcomputer.com Published On :: 2020-05-06T11:25:41-05:00 Full Article
2 Can this PSU run the RTX 2080 TI By www.bleepingcomputer.com Published On :: 2020-05-08T19:19:29-05:00 Full Article
2 4 awesome discoveries you probably didn't hear about this week -- Episode 32 By feedproxy.google.com Published On :: 2019-08-31T07:00:00Z 4 awesome discoveries you probably didn't hear about this week -- Episode 32 Full Article
2 Judo Bank secures USD 230 mln in funding round By feedproxy.google.com Published On :: Fri, 08 May 2020 12:26:00 +0200 Australia-based neobank Judo Bank has raised USD 230 million... Full Article
2 linked2pay launches CustomerConnect to improve B2B invoice payments By feedproxy.google.com Published On :: Fri, 08 May 2020 13:46:00 +0200 linked2pay, a US-based payments technology provider, has... Full Article
2 Compatibility:- Logitech C920 HD Pro USB 1080p Webcam and Windows 10 By www.bleepingcomputer.com Published On :: 2020-04-24T12:17:48-05:00 Full Article
2 Cash App customer support |+l.929.344.6502| number By www.bleepingcomputer.com Published On :: 2020-05-09T09:20:45-05:00 Full Article
2 Cash App customer care |+l.929.344.6502| number By www.bleepingcomputer.com Published On :: 2020-05-09T09:21:41-05:00 Full Article
2 Marriott hacked again, 5.2 million guests affected By feedproxy.google.com Published On :: Wed, 01 Apr 2020 14:42:13 +0000 Bad actors accessed a range of personally identifiable information, including names, dates of birth and a lot more The post Marriott hacked again, 5.2 million guests affected appeared first on WeLiveSecurity Full Article Cybersecurity
2 Ninja Van raises USD 279 mln after ecommerce surge By feedproxy.google.com Published On :: Tue, 05 May 2020 13:07:00 +0200 Singapore-based logistics provider Ninja Van has raised USD... Full Article
2 Back Market raises USD 120 mln for its marketplace By feedproxy.google.com Published On :: Wed, 06 May 2020 15:23:00 +0200 The France-based startup Back Market has raised a new USD... Full Article
2 Why These 2 Investment Professionals Say This Telemedicine Company Is One of Their Top Picks By feedproxy.google.com Published On :: Tue, 28 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/28/2020 As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada.News Flash: On May 7, CloudMD announced that it is partnering with IDYA4 Corp. for it to resell the health technology firm's Livecare technology in the U.S.. Read more here. News Flash: On May 4, CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. Read more here. As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic, telemedicine has taken off. Two investment professionals, Bruce Campbell and Keith Schaefer, have called CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE), a small-cap Canadian telemedicine firm, a top pick. Bruce Campbell, founder and portfolio manager of Stonecastle Investment Management, spoke about CloudMD on April 27 on BNN: "The first top pick is CloudMD Software, a technological medical play. We've tried to look at opportunities that are really going to be able to take advantage of Covid and this is one of the ones that we think is; what they do is telemedicine. "The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." - Keith Schaefer If you look back at a year ago, where everyone had to go to the doctor, and now all of the different provinces have opened up billing codes, so that now we don't have to go into a doctor's office. We can do a virtual doctor's visit and the doctor gets paid just like they do with an in-house appointment. Obviously with everything that has happened with this crisis, people really don't want to go into a doctor's office and they need a prescription renewal or something like that. If you look at CloudMD's peers in the U.S., there is a company called Teladoc, which is a big U.S. company that does the same thing. Obviously, the size of the market is different, but the multiple it trades at is multiple times higher than where CloudMD is. CloudMD is just starting to gain adoption. They started off here in BC, they have moved to Ontario, and they are going to be rolling out really across the country, so tons of opportunity for a company like this. They will probably change the way that we view our doctor and our healthcare visits going forward." Keith Schaefer, editor and publisher of Oil & Gas Investments Bulletin, is also following CloudMD, and wrote: "An entirely newand highly profitableindustry is being borne out in 2020TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play TeleHealth. It's growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical RecordsEMRsystem. It has MULTIPLE revenue streams and it just moved into Canada's largest marketOntariosetting up an even faster growth rate. The recent spread of coronavirus is only accelerating this. Covid-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don't want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth. TeleHealth companies in Canada are getting paid more money for services than bricks-and-mortar clinics, and have a fraction of the costs. Doctors want more of it, patients want more of it, government wants more of itand the Market REALLY wants more of it. Everybody wins here; there is no downside. The rapid scale-up and profitability is key for investors. CloudMD is established, growing quickly and trading at a fraction of its peers. The average multiple of competitors in the sector trade at 5-7x revenue, and CloudMD is trading way below that at 2.5x per revenue. But realize that the Canadian use of telemedicine is still just a fraction of where it is in the U.Sso the quick, early upside is even bigger. The market desperately wants to own TeleHealth right now. I see CloudMD as the best way to do that in the junior sector (where the leverage is!). For this stock to have a major run all that needs to happen is for institutional investors to wake-up to the fact that the company exists. That's happening now with the company entering the province of Ontariowhich has 14.5 million peopleover one-third of Canada's population. CloudMD is a fully integrated health care companykind of like a hospital-in-the-sky. They do have five bricks-and-mortar clinics, but they also own their own EMRElectronic Medical Recordssystem that operates in eight provinces and is used by over 3,000 doctors and is supported by an in-house 25 person development team. They have their own CloudMD appwhich has over 100,000 registered patients already. The EMR gives CloudMD a recurring monthly revenue stream, which The Street loves. The app gives them high-margin fees from doctors, specialists and groups like massage therapists & counselors. These people are revenue, not costs. As I said, full hospital-in-the-sky. Multiple revenue sources with lower costs. To schedule a virtual doctor's appointment all that a patient has to do is download the free CloudMD app and then arrange an appointment with one of the doctors. There is zero charge for the patient and they can see a doctor very quickly. CloudMD can scale up the number of patients VERY quicklyand they are. Every aspect of healthcare that's very fractured and disjointed will now be in the one CloudMD ecosystem. Everyone wins with this system. Patients, doctors, the medical system, society, even investors. Everyone. Doctors who have signed up with CloudMD work remotely from home or wherever they are (like their winter home down south). The rapid scale-up potential excites me. CloudMD can add in unlimited number of doctors and patientsso it has a virtually unlimited ability to scale quickly with little incremental cost. Profit margins are wide and there is no cap on the number of customers that can be handled. After a patient has an appointment, CloudMD bills the government directly just like every bricks-and-mortar clinic in Canada does. CloudMD records 100% of the revenue and gets to keep 30% of the billing for every patient that is seen through telemedicine, which is actually 10% more than what a bricks-and-mortar clinic receives. That is because the governments are trying to push TeleHealth. The doctor gets the other 70% and doesn't have to deal with any headaches of commuting or running a business. Without the overhead of a bricks-and-mortar clinic, AND more revenue, CloudMD will be much more profitable than traditional healthcare stocks. Faster scale, more cash flow. And they just entered Canada's largest market. This is the right stock in the right market at the right time. That's the great thing about this business model. It's very scalable, very easy, and it grows very quickly. CloudMD has been growing its recurring SAAS (Software-as-a-Service) revenue by 30% YoY with its EMR system. But this year the company is expecting that doctor growth to be much much higherwith a new full time sales team and the coronavirus pandemic. SaaS revenue is highly lucrative! The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." Read Keith Schaefer's entire article here. Watch Bruce Campbell of StoneCastle Investments share his top picks: CloudMD, Lightspeed and Viemed. Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Keith Schaefer: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: CloudMD. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: CloudMD. My company has a financial relationship with the following companies mentioned in this article: None. Additional disclosures are listed below. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with CloudMD. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of CloudMD. Please click here for more information. 3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy. 4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of CloudMD, a company mentioned in this article. Additional Disclosures Keith Schaefer Disclosures: CloudMD has reviewed and sponsored this article. The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom. Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Keith Schaefer is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity. Bruce Campbell, Stonecastle Investment Management: A guest firm/affiliate holds a position in CloudMD. There is no guest position held, members of his household do not hold positions and CloudMD is not an investment banking client. ( Companies Mentioned: DOC:CSE; DOCRF:OTCQB; 6PH:FSE, ) Full Article
2 Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results' By feedproxy.google.com Published On :: Wed, 22 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/22/2020 The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report.In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can-Fite BioPharma Ltd.'s (CANF:NYSE.MKT) Phase 2 trial of Namodenoson for nonalcoholic fatty liver disease with or without nonalcoholic steatohepatitis "look pretty good." He added that "the consistency of the data from the studies (preclinical and clinical), should support business development interest." Dawson James has a $9 per share target price on Can-Fite; the stock is currently trading at around $1.75 per share. Kolbert recapped the study design and provided the results. This purpose of this multicenter, randomized, double-blinded, placebo-controlled trial involving 60 patients was to determine dose efficacy and safety. Patients were treated twice a day with either 12.5 milligrams or 25 milligrams of oral Namodenoson or a placebo for 12 weeks. The primary endpoint was effect on inflammation, measured by mean percent change from baseline in alanine transaminase blood levels and safety. The second endpoints included the percent change from baseline in liver fat, as determined by MRI proton density fat fraction. In terms of safety, study participants tolerated Namodenoson at both doses, and no adverse events were reported. Otitis media occurred in two patients but was deemed to be unrelated to the drug. The four other events that occurred that were drug related were mild and self-limited. Regarding efficacy of Namodenoson, Kolbert noted that "for a small Phase 2 exploratory study, there appears to be a significant efficacy signal." Kolbert provided updates on other Can-Fite clinical trials. The company's COVID-19 trial is now designed. Plans call for it to be randomized, open label, and double armed with Piclidenoson administered plus standard supportive care, compared to standard supportive care alone, in 40 hospitalized COVID-19-infected patients with moderate to severe symptomatic disease. Patients are to be randomized at a 1:1 ratio to one of the trial arms and treated for up to four weeks. The primary efficacy measures will be time to resolution of viral shedding, time to resolution of clinical symptoms, respiratory function, need for ventilatory support and overall mortality. Piclidenoson, Can-Fite's lead drug candidate, also is in Phase 3 in two indications: moderate to severe rheumatoid arthritis (the ACROBAT study) and moderate to severe plaque psoriasis (the COMFORT study). Enrollment for both trials is more halfway complete. In both, Piclidenoson "hold great promise as alternative therapies with what appears to be a more favorable side effects profile," Kolbert commented. Dawson James has a Buy rating on Can-Fite BioPharma. Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. Disclosures for Dawson James Securities, Can-Fite BioPharma Ltd., April 20, 2020, The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering. Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities. Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analysts compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. ( Companies Mentioned: CANF:NYSE.MKT, ) Full Article
2 Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS By feedproxy.google.com Published On :: Fri, 24 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/24/2020 Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L.Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) today announced that it had achieved an "83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days." The company stated that of the 12 patients treated, 75% (9/12) successfully came off ventilator support after a median timeframe of 10 days. The firm advised that all of the patients were treated under an emergency Investigational New Drug (IDA) application or expanded access protocol at Mt. Sinai hospital in New York City and so far seven of the patients have been discharged from the hospital. The company noted that each of the patients had received a variety of experimental agents prior to being treated with remestemcel-L. The firm explained that until now only about 9% (38/445) of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated with existing standard of care treatments during March and April 2020. The company reported that at a second major referral hospital network in New York City over the same period, there was 88% mortality with only 12% survival (38/320) among ventilator-dependent COVID-19 patients. The company's CEO Dr. Silviu Itescu commented, "The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients." Dr. Fred Grossman, Mesoblast's Chief Medical Officer, added, "There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS." Mesoblast Ltd. is headquartered in Melbourne, Australia, and is a developer of industrial-scale, cryopreserved, off-the-shelf allogeneic cellular medicines. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform in order to create a wide portfolio of commercial products and late-stage product candidates. The firm indicated that "the Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease has been accepted for priority review by the U.S. Food and Drug Administration." The company has offices in Australia, the U.S. and Singapore. Mesoblast began the day with a market capitalization of around $687.9 million with approximately 106.7 million shares outstanding. MESO shares opened nearly 142% higher today at $15.59 (+$9.14, +141.71%) over yesterday's $6.45 closing price and reached a new 52-week high price this morning of $20.57. The stock has traded today between $13.01 and $20.57 per share and is presently trading at $14.76 (+$8.30, +128.76%). Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice. ( Companies Mentioned: MESO:NASDAQ; MSB:ASX, ) Full Article
2 Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients By feedproxy.google.com Published On :: Wed, 29 Apr 2020 00:00:00 PST Source: Streetwise Reports 04/29/2020 Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19.Biopharmaceutical company Chimerix Inc. (CMRX:NASDAQ), which focuses on developing medicines to treat cancer and other serious diseases, today announced that it will initiate a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients suffering from acute lung injury (ALI). The firm explained that "DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin." Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School commented, "Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19...Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection." The company's CEO Mike Sherman remarked, " DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications...We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection." The company outlined its plans for the study indicating that it will be a randomized, double-blind Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at a high risk of respiratory failure. The study subjects will be confirmed COVID-19 patients who require hospitalization and supplemental oxygen therapy. The primary endpoint established in the study is the percentage of subjects who survive and do not require mechanical ventilation through 28 days. Several secondary endpoints listed include time needed for showing improvement, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality and changes in several key biomarkers. The study will begin by enrolling 24 subjects in Phase 2 to first establish dosage levels and then expand to 74 total patients. The firm advised that if Phase 2 results are positive, it would enroll approximately 450 subjects in the Phase 3 portion of the study. The company reported that "the clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation." The firm indicated that the mechanisms of action of DSTAT may address overactive inflammatory response including underlying causes of blood coagulation disorders associated with COVID-19. Chimerix is a development-stage biopharmaceutical company based in Durham, N.C. which is engaged in advancing medicines in the areas of cancer and other serious diseases. The company listed that it presently has two active clinical-stage development programs. The first is dociparstat sodium (DSTAT) which is a glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity. The second pipeline candidate is brincidofovir (BCV) which is an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix began the day with a market capitalization of around $93.2 million with approximately 61.74 million shares outstanding. CMRX shares opened 30% higher today at $1.97 (+$0.46, +30.46%) over yesterday's $1.51 closing price. The stock has traded today between $1.82 to $2.62 per share and is currently trading at $2.27 (+$0.76, +50.33%). Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice. ( Companies Mentioned: CMRX:NASDAQ, ) Full Article
2 Seattle Genetics Shares Trade Higher on Q1/20 Earnings and 22% Growth in ADCETRIS Sales By feedproxy.google.com Published On :: Fri, 01 May 2020 00:00:00 PST Source: Streetwise Reports 05/01/2020 Seattle Genetics shares traded 8% higher, reaching a new 52-week high, after the company reported Q1/20 financial results which included a 10% y-o-y increase in net revenues fueled by a 22% increase in sales of ADCETRIS® and a strong debut for PADCEV in its first full quarter of sales.Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020. The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA (tucatinib). The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth." The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million. The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19." The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675700 million, royalty revenues of $105115 million and collaboration and license agreement revenues of $3050 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860950 million with SG&A expenses of $475525 million. Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines. Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%). Sign up for our FREE newsletter at: www.streetwisereports.com/get-news Disclosure: 1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None. 2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. 3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. 4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. 6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice. ( Companies Mentioned: SGEN:NASDAQ, ) Full Article
2 Episode 962 Scott Adams: No One Knows Anything But We Still Have to Decide How to reopen Economy By feed.dilbert.com Published On :: Fri, 08 May 2020 16:11:14 +0000 My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: The Plague of Corruption video General Flynn San Antonio makes phrase “Chinese virus” hate speech Vitamin D deficiency and coronavirus Testing, flattening the curve, magical thinking If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots […] The post Episode 962 Scott Adams: No One Knows Anything But We Still Have to Decide How to reopen Economy appeared first on Scott Adams' Blog. Full Article Podcast Coronavirus General Flynn Hydroxychloroquine Judy Mikovits Kent Heckenlively Plague of Corruption politics president trump Scott Adams Vitamin D
2 2020 Outlook Favorable for Texas Oil & Gas Company By feedproxy.google.com Published On :: Tue, 31 Mar 2020 00:00:00 PST The elements of Goodrich Petroleum that make it a Buy are presented in a ROTH Capital Partners report. Full Article
2 Solar Energy Firm Signs Large Deal for New York Project, 1215 Times Its Average Size By feedproxy.google.com Published On :: Thu, 02 Apr 2020 00:00:00 PST This project, along with two other new projects, increases the company's order backlog by 65%. Full Article UGE:TSX.V; UGEIF:OTCQB
2 Tankers Are the Big Winners of the 2020 Oil Crash By feedproxy.google.com Published On :: Wed, 08 Apr 2020 00:00:00 PST With onshore storage becoming increasingly scarce, the volume of oil being stored on ships will continue to rise, delivering a once-in-a-generation opportunity for oil tankers, according to McAlinden Partners. Full Article
2 Energous Shares Charge 200% Higher After Receiving FCC Certification for Wireless Charging Technology By feedproxy.google.com Published On :: Tue, 21 Apr 2020 00:00:00 PST Shares of Energous Corp. skyrocketed after the company reported that it received certification from the FCC for its new, "groundbreaking" over-the-air, power-at-a-distance wireless charging WattUp® technology. Full Article
2 Kraton Share's Rise on Positive Q1/20 Earnings Report By feedproxy.google.com Published On :: Thu, 30 Apr 2020 00:00:00 PST Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19. Full Article
2 Texas Oil & Gas Firm Achieves EBITDA, EPS Beats in Q1/20 By feedproxy.google.com Published On :: Thu, 07 May 2020 00:00:00 PST A recap of Parsley Energy's Q1/20 performance and projections for this year and next are given in a Raymond James report. Full Article
2 New holistic method for assessing Natura 2000 landscapes By ec.europa.eu Published On :: Thu, 13 Oct 2011 16:19:21 +0100 High quality landscape assessments of areas protected under the Natura 2000 network are critical for effective long-term management plans. In a recent study, scientists have presented a integrated assessment of a Natura 2000 site in Sicily, Italy, which not only considers preservation of environmental features, as required by Natura 2000, but also human features, such as places of historical interest or industrial activity. Full Article
2 The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million to By ec.europa.eu Published On :: Thu, 7 Feb 2013 11:44:52 GMT The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million tonnes of construction waste into different materials. The researchers suggest that the study provides an important reference for other countries working to minimise construction waste. Full Article
2 Wind & solar energy and nature conservation – January 2015 By ec.europa.eu Published On :: Thu, 29 Jan 2015 9:23:19 GMT Efforts to address climate change and protect natural ecosystems can – and need to – benefit each other. But conflicts can arise. This Future Brief focuses on how land-based ecosystems are affected by wind and solar photovoltaic (PV) development, and how win-win solutions which maximise both conservation and climate benefits may be developed. Recommendations include careful site planning, regeneration and enhancement, and use of multi-level ecosystem data. Full Article
2 Very high CO<sub>2</sub> levels decrease yield and antioxidant content of some green vegetables By ec.europa.eu Published On :: Thu, 07 Apr 2016 09:12:34 GMT Increases in the amount of CO<sub>2</sub> in the atmosphere can be beneficial to crops, by providing a source of carbon for growth. However, very high levels of CO<sub>2</sub> have the reverse effect, decreasing the yield and quality of vegetable crops, a new study has shown. The researchers say atmospheric CO<sub>2</sub> concentration should be kept below 5 000 ppm to enhance the yield of leafy vegetables such as cabbage and lettuce. Full Article
2 Ecological effects of deep-sea mining experiment still evident 26 years later By ec.europa.eu Published On :: Fri, 06 Mar 2020 10:51:58 GMT In 1989, researchers dragged a plough harrow across the seafloor of the Peru Basin to recreate some of the effects of deep-sea mining. Twenty-six years later, a new team of researchers returned to the site to assess whether there were any long-term ecological effects. They found that the seabed ecosystem remained disrupted, with significantly fewer suspension feeder species, such as anemones and sea sponges, than in undisturbed areas of seafloor. This suggests that deep-sea mining could cause irreversible changes to marine food webs in highly disturbed areas. Full Article
2 Shifts in cropland and trade patterns could feed the world in 2050 — but no easy solution to future food and water security By ec.europa.eu Published On :: Thur, 16 Apr 2020 12:35:30 GMT How can we grow more crops without taking too much water away from freshwater ecosystems for irrigation? A new study indicates that it is possible to double crop production by 2050 without exceeding set limits for water extraction if more crops are grown in regions with higher rainfall and with corresponding shifts in international trade and agricultural management. However, without appropriate safeguards, and if we follow the current business-as-usual scenario, this could come at the ecological cost of converting natural land and forest into cropland. This research provides a ‘first-step’ in analysing potential trade-offs in the global food-trade-water nexus. Full Article
2 The Week in Ransomware - May 8th 2020 - Attacks Continue By www.bleepingcomputer.com Published On :: Fri, 08 May 2020 18:43:14 EDT Ransomware operators continue their worldwide attacks against healthcare organizations and businesses, while leaking the data of victims who do not pay a ransom. [...] Full Article Security
2 North Korean hackers infect real 2FA app to compromise Macs By www.bleepingcomputer.com Published On :: Sat, 09 May 2020 12:39:40 EDT Hackers have hidden malware in a legitimate two-factor authentication (2FA) app for macOS to distribute Dacls, a remote access trojan associated with the North Korean Lazarus group. [...] Full Article Security
2 Scientists on the prowl for 'the ultimate Pokémon' By esciencenews.com Published On :: Wed, 17 Aug 2016 14:14:36 +0000 Researchers are on a real-life search for what one calls "the ultimate Pokémon": Zenkerella, an elusive scaly-tailed squirrel that has never been spotted alive by scientists. However, biologists recently found three newly dead specimens that hint at how the "living fossil" has evolved over the past 49 million years. read more Full Article Paleontology & Archaeology
2 Researchers name a new species of reptile from 212 million years ago By esciencenews.com Published On :: Thu, 08 Sep 2016 19:39:18 +0000 An extinct reptile related to crocodiles that lived 212 million years ago in present day New Mexico has been named as a new species, Vivaron haydeni, in a paper published this week by Virginia Tech's Department of Geosciences researchers. read more Full Article Paleontology & Archaeology
2 New holistic method for assessing Natura 2000 landscapes By ec.europa.eu Published On :: Thu, 13 Oct 2011 16:28:42 +0100 High quality landscape assessments of areas protected under the Natura 2000 network are critical for effective long-term management plans. In a recent study, scientists have presented a integrated assessment of a Natura 2000 site in Sicily, Italy, which not only considers preservation of environmental features, as required by Natura 2000, but also human features, such as places of historical interest or industrial activity. Full Article
2 http://ec.europa.eu/environment/integration/research/newsalert/pdf/334na2.pdf By ec.europa.eu Published On :: Thu, 27 Jun 2013 11:59:56 +0100 The development of Green Infrastructure (GI) in a UK case study has been researched in a recent study. Some issues caused by an imbalance in stakeholder power and conflicting roles played by major stakeholders were identified with the project. Stakeholder participation is central to the concept of GI and the research reiterates the importance for those implementing GI to ensure that participation is effective and balanced. Full Article